Breaking News
0

Loxo Oncology Inc (LOXO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Loxo Oncology Inc's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Loxo Oncology Inc is no longer active, quotes are not updating
234.66 0.00    0.00%
14/02 - Closed. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US5488621013 
CUSIP: 548862101
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 234.66 - 234.88
Loxo Oncology Inc 234.66 0.00 0.00%

LOXO Overview

 
This is the main Loxo Oncology Inc stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close234.73
Day's Range234.66 - 234.88
Revenue144.8M
Open234.7
52 wk Range104.92 - 234.93
EPS - 2.08
VolumeN/A
Market Cap7.18B
Dividend (Yield)N/A (N/A)
Average Vol. (3m)1,064,815
P/E RatioN/A
Beta2.49
1-Year Change43.03%
Shares Outstanding30,614,536
Next Earnings DateN/A
What is your sentiment on Loxo Oncology Inc?
or
Market is currently closed. Voting is open during market hours.

Loxo Oncology Inc News


Loxo Oncology Inc Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Strong Sell Strong Sell Neutral Buy Buy
Technical Indicators Sell Sell Neutral Strong Buy Strong Buy
Summary Strong Sell Strong Sell Neutral Strong Buy Strong Buy

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Three Outside Up 1M Current
Doji Star Bearish 1M Current
Completed Patterns
Bullish Engulfing 1M 1 Jan 19
Advance Block Bearish 1M 11 Mar 18
Three Black Crows 1W 12 Nov 18, 2018

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 235.32 237.65 234.88 -0.55 -0.23% 21.69M 15:59:59  
  AMD 30.72 30.92 30.17 +0.19 +0.62% 41.50M 15:59:59  
  Facebook 188.89 190.38 183.66 +5.61 +3.06% 14.95M  
  Alphabet A 1,242.24 1,247.13 1,220.92 +24.47 +2.01% 1.37M 15:59:59  
  Amazon.com 1,767.38 1,776.45 1,740.62 +30.95 +1.78% 3.10M 15:59:59  
  IBM 143.00 143.72 141.81 +0.96 +0.68% 3.00M 15:59:59  
  Tesla 257.89 260.00 254.12 +0.93 +0.36% 6.43M  
  Roku 132.82 132.95 122.53 +13.70 +11.50% 26.39M 15:59:59  
  Alibaba ADR 175.29 176.75 172.69 +4.13 +2.41% 13.72M 15:59:59  
  Microsoft 141.58 141.79 139.81 +2.02 +1.45% 19.44M 15:59:59  

Loxo Oncology Inc Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

96

Equity Type

ORD

Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
Securities Investor Protection Corporation (United States) $0 Start Trading
National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States) $500 Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LOXO Comments

Write your thoughts about Loxo Oncology Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sekar Marimuthu
Sekar Marimuthu Jan 07, 2019 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why it's increased
Leonid Agureev
Leonid Agureev Jan 07, 2019 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Lilly to buy Loxo Oncology in $8 billion cancer push
Sekar Marimuthu
Sekar Marimuthu Jan 07, 2019 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
thanks
Sekar Marimuthu
Sekar Marimuthu Jan 07, 2019 9:45AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
yes I have seen
Mi Michal
Mi Michal Nov 02, 2018 7:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They will get FDA for their drug Larotrectinib before November 26!! And the drug is amazingly efficient! Loxo will get!!!
Sekar Marimuthu
Sekar Marimuthu Nov 02, 2018 7:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
good
Sekar Marimuthu
Sekar Marimuthu Nov 02, 2018 7:48PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ur genius
Nick LaRue
Nick LaRue Dec 19, 2017 1:17PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock is going to ****up this year
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email